Ibrutinib As Treatment for Chemoimmunotherapy-Resistant Patients with Follicular Lymphoma: First Results from the Open-Label, Multicenter, Phase 2 DAWN Study
Ajay K. Gopal(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Gilles Salles(Memorial Sloan Kettering Cancer Center), Michael Lill(Cedars-Sinai Medical Center), Georg Heß(Johannes Gutenberg University Mainz), Dzhelil Osmanov, Peter Martin(Northwestern University), Nathan Fowler(Repligen (United States)), Jessica Vermeulen(UPMC Hillman Cancer Center), Abdulraheem Yacoub(The University of Kansas Cancer Center), Sriram Balasubramanian(Pharmacyclics (United States)), Shean‐Sheng Wang(UPMC Hillman Cancer Center), Stephen J. Schuster(Hospital of the University of Pennsylvania), Gary Gartenberg(UPMC Hillman Cancer Center), Judith Trotman(The University of Sydney), Sanjay Deshpande(Aurora Sinai Medical Center), Wojciech Jurczak(Jagiellonian University), Umberto Vitolo(Candiolo Cancer Institute), James Morton(UPMC Hillman Cancer Center), Jing‐Zhou Hou(Center for Cancer and Blood Disorders)
Cited by 9
Related Papers
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
|Journal of Clinical Oncology|2012|1.1k
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
|Nature Medicine|2015|1.1k